Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.

Saved in:
Bibliographic Details
Title: Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
Authors: Ott, P. A.1 patrick_ott@dfci.harvard.edu, Piha-Paul, S. A.2, Munster, P.3, Pishvaian, M. J.4, van Brummelen, E. M. J.5, Cohen, R. B.6, Gomez-Roca, C.7, Ejadi, S.8, Stein, M.9, Chan, E.10, Simonelli, M.11, Morosky, A.12, Saraf, S.12, Emancipator, K.12, Koshiji, M.12, Bennouna, J.13
Source: Annals of Oncology. May2017, Vol. 28 Issue 5, p1036-1041. 6p. 3 Charts, 1 Graph.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdx029